Incb053914

Author: fzfz

August undefined, 2024

WebINCB053914 (INCB-053914) is a novel potent, and selective ATP-competitive, pan-PIM kinase inhibitor with IC50 of 0.24/30.0/0.12 nM for PIM1/2/3, respectively; INCB053914 is highly selective against a panel of more than 50 kinases (>475-fold selectivity) with exception of RSK2 ... WebJan 14, 2024 · Chemsrc provides INCB053914 phosphate(CAS#:2088852-47-3) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of INCB053914 phosphate are included as well.

Abstract 5416: Activity of the pan-PIM kinase inhibitor INCB053914 …

WebJan 5, 2024 · Treatment with PIM inhibitors sensitizes cells to chemotherapies that would normally be exported by ATP-binding cassette (ABC) drug transporters ( 62 ), and this has been shown to be mediated through both a decrease in the activity of ABC transporters, as well as reduced levels ( 63 ). WebINCB053914 in combination with select standard of care (SOC) agents and will identify the optimal INCB053914 dose in combination with conventional SOC regimens to take … open virgin money app

INCB053914 and Pomalidomide With Dexamethasone for …

WebDec 8, 2024 · An ongoing 4-part, phase 1/2 study is evaluating INCB053914, a small-molecule pan-PIM inhibitor, in patients with advanced hematologic malignancies (NCT02587598). Results from part 1 (monotherapy dose escalation), including preliminary safety, pharmacokinetics (PK), and pharmacodynamics (PD) are reported. WebJun 21, 2024 · INCB053914 potently inhibited the activities of all three PIM isozymes, which is important for avoiding compensatory activity and for maximizing therapeutic efficacy [33, 34, 73]. PIM447 and AZD1208 are also potent and selective pan-PIM inhibitors that show similar activity in vitro and in vivo to INCB053914 [35, 37, 54]. WebINCB053914 phosphate is an inhibitor of Pim extracted from patent WO 2024044730 A1, compound 1; has an IC50 of less than 35 nM. Solubility * In vitro: DMSO 48 mg/mL (78.49 mM) * <1 mg/ml means slightly soluble or insoluble. ipdm services india pvt ltd

Study of INCB053914 in Subjects With Advanced Malignancies

WebJun 21, 2024 · Reported here is a preclinical characterization of INCB053914, a novel, potent, and selective adenosine triphosphate-competitive pan-PIM kinase inhibitor. In … INCB053914 is a recently described pan-PIM kinase inhibitor that exhibits potent activity against PIM1, PIM2, and PIM3 (biochemical 50% inhibitory concentration [IC 50] values of 0.24, 30, and 0.12 nM, respectively). 40 To assess the effects of INCB053914 on JAK2 V617F-driven cell growth, we determined the concentration for 50% of maximal ... ipd msciWebStudy of INCB053914 in Subjects With Advanced Malignancies Jacksonville, FL This is an open-label, dose-escalation study of the proviral integration site of Moloney murine leukemia virus (PIM) kinase inhibitor INCB053914 in subjects with advanced malignancies. The study will be conducted in 4 parts. ipdm software

"WebNov 26, 2024 · INCB053914 is a recently described pan-PIM kinase inhibitor that exhibits potent activity against PIM1, PIM2, and PIM3 (biochemical 50% inhibitory concentration [IC 50] values of 0.24, 30, and 0.12 nM, respectively). 40 To assess the effects of INCB053914 on JAK2 V617F -driven cell growth, we determined the concentration for 50% of maximal … " - Incb053914

Incb053914

Myeloproliferative Disorders Clinical Trials - Mayo Clinic Research

WebINCB053914 (INCB-053914) is a novel potent, and selective ATP-competitive, pan-PIM kinase inhibitor with IC50 of 0.24/30.0/0.12 nM for PIM1/2/3, respectively. Purity : >98% …

Did you know?

WebSep 26, 2024 · A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma A Phase 1b, Multicenter, Open-Label Study of the Safety and Tolerability of INCB053914 in Combination With INCB050465 in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Overall Status Completed … WebStudy of INCB053914 in Subjects With Advanced Malignancies The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. ClinicalTrials.gov Identifier: NCT02587598

WebFeb 25, 2024 · The study will be conducted in 4 parts. Part 1 (monotherapy dose escalation) will evaluate safety and determine the maximum tolerated dose of INCB053914 monotherapy and the recommended phase 2 dose(s) (a tolerated pharmacologically active dose that will be taken forward into the remaining parts of the study). WebDescription: INCB053914, also known as Uzansertib, is a novel, potent, and selective adenosine triphosphate-competitive pan-PIM kinase inhibitor. In vitro, INCB053914 inhibited proliferation and the phosphorylation of downstream substrates in cell lines from multiple hematologic malignancies.

WebINCB053914 (INCB-053914) is a novel potent, and selective ATP-competitive, pan-PIM kinase inhibitor with IC50 of 0.24/30.0/0.12 nM for PIM1/2/3, respectively. Purity : >98% (HPLC) COA Datasheet HNMR HPLC MSDS Handing Instructions Group Booking Get Quotation Bulk Inquiry Add to Cart Biological Information Product Name INCB053914 Note WebAug 1, 2015 · INCB053914 is a novel, ATP-competitive, small molecule, pan-inhibitor of PIM kinases. In biochemical assays, INCB053914 is potent against PIM1, PIM2 and PIM3 and …

WebNov 26, 2024 · INCB053914 is a recently described pan-PIM kinase inhibitor that exhibits potent activity against PIM1, PIM2, and PIM3 (biochemical 50% inhibitory concentration …

WebDec 7, 2024 · Conclusions: INCB053914 monotherapy demonstrated preliminary safety in Part 1; elevated ALT/AST were the most common treatment-related TEAEs and DLTs, and … open vision imagesWebINCB053914, an ATP-competitive PIM inhibitor, has been tested as a monotherapy for the treatment of multiple hematological malignancies, including AML, multiple myeloma, and lymphoma [67]. The... openvino vswhere tool is not foundWebergistic inhibition of tumor growth was observed when INCB053914 was combined with selective PI3Kδ inhibition, selective JAK1 or JAK1/2 inhibition, or cytarabine. Based on these data, pan-PIM kinase inhibitors, including INCB053914, may have therapeutic utility in hematologic malignancies when combined with other inhibitors of oncogenic kinases or ipd near meWebDec 7, 2024 · Together, these data suggest that the pan-PIM inhibitor INCB053914 may provide a highly effective novel anti-MPN therapeutic, particularly in combination with ruxolitinib. INCB053914 is currently under investigation in a Phase 1/2 study in patients with advanced hematological malignancies (ClinicalTrials.gov: NCT02587598). ipdn e learningWebOct 27, 2015 · Initial cohort dose of INCB053914 at the protocol-specified starting dose in two treatment groups in dose escalation, with subsequent expansion in up to five cohorts … open virgin cash isaWebThe sum referred to in paragraph (2) is the sum of the deductions under this chapter which are directly connected with the debt-financed property or the income therefrom, except … open virgin money accountWebUzansertib (INCB053914) phosphate is an orally active, ATP-competitive pan- PIM kinase inhibitor with IC50 s of 0.24 nM, 30 nM, 0.12 nM for PIM1, PIM2, PIM3, respectively. … ipdm teamcenter